February 1998
EDITORIAL |
 |
Better Safe Than SorryDoes reducing viral load reduce the risk of transmitting HIV?PAUL A. VOLBERDING, M.D. |
THERAPEUTIC ADVANCES |
|
The Next Generation of Antiretroviral AgentsPotent and promising new drugs will soon be available to combat HIV infectionHAROLD A. KESSLER, M.D. |
NEWSLINE |
|
NEWSLINE ... NEWSLINE ... NEWSLINE ...Fomivirsen proves effective against CMV retinitis ... Patients are warned not to resume taking abacavir if they have an allergic reaction to it ... d4T plus 3TC, a therapeutic option in people who develop resistance to AZT ... "Protease paunch" and "buffalo hump": Combination therapy can lead to unusual fatty deposits ... Sustiva® now available to anyone with a CD4 count below 400 ... HAART therapy leads to resolution of MAC infection ...Plus: what this means for you: HIV experts tell you, in clear, concise language, what impact these developments are likely to have on your day-to-day life. |
PULL OUT AND SAVE |
|
Clinical Trials You May Wish to Enroll InA list of current clinical trials that involve various combinations of anti-HIV drugs, some of which cannot otherwise be obtained by people living with HIV infection |
CONTINUING CARE |
|
Better Treatment for CMV RetinitisNew drugs and new strategies can slow disease progressionMARK A. JACOBSON, M.D.
|